<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28232" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ranitidine (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Morgan</surname>
            <given-names>Katie A.</given-names>
          </name>
          <aff>Marshfield Clinic Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahlawat</surname>
            <given-names>Rajni</given-names>
          </name>
          <aff>Marshfield Clinic Un Wisconsin-Madison</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Katie Morgan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rajni Ahlawat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28232.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">On April 1, 2020, The FDA announced that it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market due to contamination with nitrosodimethylamine (NDMA). This article is only of historical interest.</p>
        <p>Ranitidine was FDA-approved for both adults and children aged 1 month to 16 years. Ranitidine, over-the-counter for self-care use without a prescription, was only FDA-approved in children older than 12 years.</p>
        <p>
<bold>FDA-Approved&#x000a0;Ranitidine Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Benign gastric ulcer disease, short-term, and maintenance</p>
          </list-item>
          <list-item>
            <p>Duodenal ulcer disease, short-term, and maintenance</p>
          </list-item>
          <list-item>
            <p>Erosive esophagitis</p>
          </list-item>
          <list-item>
            <p>Hypersecretory conditions (e.g., Zollinger-Ellison, systemic mastocytosis, multiple endocrine adenoma syndrome)&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gastroesophageal reflux disease (GERD)</p>
          </list-item>
          <list-item>
            <p>Non-ulcer dyspepsia, indigestion, heartburn, and sour stomach</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA-Approved&#x000a0;Ranitidine Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anaphylaxis<xref ref-type="bibr" rid="article-28232.r1">[1]</xref><xref ref-type="bibr" rid="article-28232.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>NSAID-induced ulcer prophylaxis<xref ref-type="bibr" rid="article-28232.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Stress ulcer prophylaxis<xref ref-type="bibr" rid="article-28232.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Taxane-related urticaria prophylaxis<xref ref-type="bibr" rid="article-28232.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Aspiration prophylaxis during obstetric anesthesia<xref ref-type="bibr" rid="article-28232.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28232.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Mechanism</bold>
</p>
        <p>Ranitidine is a competitive inhibitor of histamine H2-receptors. The reversible inhibition of H2-receptors in gastric parietal cells results in a reduction in both gastric acid volume and concentration. Ranitidine&#x02019;s acid-lowering effect is more pronounced for basal and nocturnal acid secretion than it is for food-stimulated acid secretion. Additional indirect effects of ranitidine are decreased pepsin secretion and increased nitrate-reducing bacterial flora.</p>
        <p>
<bold>Pharmacokinetics and Pharmacodynamics</bold>
</p>
        <p>When dosed orally, ranitidine has a bioavailability of 50%, which is relatively unaffected by food. The peak levels occur 2 to 3 hours post-administration for oral administration and occur 15 minutes after intramuscular administration. Ranitidine is primarily excreted unchanged in the urine, with a half-life ranging from 2.5 to 3 hours, and because of the renal elimination, the half-life may increase to 4 to 5 hours in patients with kidney dysfunction.</p>
      </sec>
      <sec id="article-28232.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Oral</bold>
</p>
        <p>Ranitidine is available as tablets, capsules, or oral syrup. Ranitidine solution or the dissolved tablet may be mixed with select enteral tube feeding solutions. <xref ref-type="bibr" rid="article-28232.r7">[7]</xref>&#x000a0;</p>
        <p>
<bold>Intramuscular (IM)</bold>
</p>
        <p>Administer as an undiluted solution.&#x000a0;&#x000a0;</p>
        <p>
<bold>Intravenous (</bold>
<bold>IV)&#x000a0;&#x000a0;</bold>
</p>
        <p><italic toggle="yes">Intermittent IV bolus:</italic> Dilute with a compatible IV solution prior to use to a maximum concentration of 2.5 mg/mL. Then the solution may be administered at a maximum rate of 10 mg per minute.</p>
        <p><italic toggle="yes">Intermittent IV infusion</italic>: Dilute with a compatible IV solution prior to use to a maximum concentration of 0.5 mg/mL. Then the solution may be administered at a maximum rate of 2.5 to 3.5 mg per minute.</p>
        <p><italic toggle="yes">Continuous IV infusion:</italic> Dilute 150 mg ranitidine in 250 mL of a compatible IV solution. This solution then may be administered at a rate of 6.25 mg per hour. For patients with Zollinger-Ellison disease, a faster infusion rate may be required.&#x000a0; Dilute prior to use to a maximum concentration of 2.5 mg/mL. Then the infusion may be started at a rate of 1 mg/kg per hour to a maximum dose of 2.5 mg/kg per hour. Ranitidine may be added to total parenteral nutrition. However, its stability varies greatly&#x000a0;depending on the specific ingredients, concentrations, and packaging of the final product.<xref ref-type="bibr" rid="article-28232.r8">[8]</xref></p>
      </sec>
      <sec id="article-28232.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The initial clinical trials for ranitidine reported the following adverse effects following oral or parenteral administration (frequency not defined):</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Central nervous system (CNS):</italic>&#x000a0;Malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, and hallucinations.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Cardiovascular:</italic>&#x000a0;Tachycardia, bradycardia, asystole, atrioventricular block, and premature ventricular beats. Bradycardia may be more frequent with rapid intravenous administration and in patients with cardiac rhythm disturbances.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Gastrointestinal (GI):</italic>&#x000a0;Constipation, diarrhea, nausea, vomiting, abdominal discomfort, pancreatitis.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Hepatic:</italic>&#x000a0;Hepatocellular, cholestatic, or mixed hepatitis; hepatic failure</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Musculoskeletal:</italic>&#x000a0;Myalgia, arthralgia</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Hematologic:</italic>&#x000a0;Leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, agranulocytosis</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Endocrine:</italic>&#x000a0;Decreased libido, impotence, galactorrhea, gynecomastia</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Integumentary:</italic> Rash, alopecia, vasculitis</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Respiratory:</italic> Pneumonia</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Renal:</italic> Increased serum creatinine, acute interstitial nephritis</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Other:</italic> Hypersensitivity reactions, anaphylaxis</p>
          </list-item>
        </list>
        <p>Transient pain at the site of intramuscular (IM) injection has been reported. Transient local burning or itching has been reported with intravenous (IV) administration of ranitidine.&#x000a0;&#x000a0;</p>
        <p>The 2015 Beers Criteria list identifies ranitidine as a therapy that may potentially trigger or exacerbate delirium in adults older than 65 years of age. Caution should be used when treating the elderly with ranitidine. <xref ref-type="bibr" rid="article-28232.r9">[9]</xref></p>
        <p>Long-term use of ranitidine for greater than 2 years may also&#x000a0;be associated with vitamin B12 deficiency. <xref ref-type="bibr" rid="article-28232.r10">[10]</xref></p>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>Ranitidine is known to cross the placenta; however, it is still commonly used when pregnant patients require acid-suppressing therapy. Of note, increasing studies are revealing a correlation between acid-suppressing therapy use during pregnancy and the development of childhood asthma.&#x000a0;<xref ref-type="bibr" rid="article-28232.r11">[11]</xref> Likewise, ranitidine is excreted into breastmilk, and the risks and benefits of use should be discussed prior to initiating therapy.</p>
      </sec>
      <sec id="article-28232.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ranitidine is contraindicated in patients who have previously experienced a hypersensitivity reaction to ranitidine or any of the product components.&#x000a0;Small case series and analyses demonstrate conflicting results regarding cross-sensitivity among H2-receptor antagonists; caution is advised.&#x000a0; Due to differences and similarities between the chemical structures, there is speculation that some H2 blockers have less risk of cross-reactivity than others. <xref ref-type="bibr" rid="article-28232.r12">[12]</xref><xref ref-type="bibr" rid="article-28232.r13">[13]</xref><xref ref-type="bibr" rid="article-28232.r14">[14]</xref></p>
        <p>Furthermore, patients with any history of acute porphyria should avoid ranitidine because it may trigger porphyric events.</p>
        <p>Clinicians urge patients to seek professional medical care and contraindicate the over-the-counter product when they have difficulty or pain when swallowing food or have blood in vomit or stool. Concurrent use is contraindicated with other acid reducers, kidney disease, or in patients&#x000a0;younger than 12 years old.</p>
      </sec>
      <sec id="article-28232.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Efficacy Parameters</bold>
</p>
        <p>Patients should notice an improvement in symptoms. Laboratory signs of improvement would include an increase in gastric pH. For GI bleeding, the goal gastric pH is typically greater than 4. The goal gastric acid secretion in Zollinger-Ellison disease is less than 10 mEq per hour.</p>
        <p>
<bold>Additional Monitoring</bold>
</p>
        <p>For patients receiving ranitidine IV at total daily doses greater than 400 mg, daily monitoring of liver function tests (aspartate aminotransferase and alanine aminotransferase) may be warranted. For acutely ill patients, serum creatinine may also be measured to provide information for renal dose adjustments as well as to monitor for potential nephrotoxicity. When there is a concern of GI bleeding, further monitoring may include occult blood tests, hemoglobin, and hematocrit.</p>
      </sec>
      <sec id="article-28232.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Severe toxicity to ranitidine is rare, and there currently&#x000a0;is no antidote for ranitidine overdose. Patients may present with CNS depression or severe hypotension. Supportive treatment and monitoring based on the presenting symptoms may be warranted.</p>
      </sec>
      <sec id="article-28232.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>
<bold>Guidelines and Recommendations</bold>
</p>
        <p>The 2015 American Academy of Allergy, Asthma, and Immunology (AAAAI), and American College of Allergy, Asthma, and Immunology (ACAAI) anaphylaxis practice parameter describe inadequate evidence for the use of H2-blockers in the treatment of anaphylaxis; however, H2-blockers can be considered adjunct therapy after the administration of epinephrine.<xref ref-type="bibr" rid="article-28232.r1">[1]</xref><xref ref-type="bibr" rid="article-28232.r2">[2]</xref>&#x000a0;(Level II)</p>
        <p>The 2009 American College of Gastroenterology guideline for the prevention of NSAID-related ulcer complications conclude that double-strength H2-blockers may reduce the risk of NSAID-induced endoscopic peptic ulcers. However, this guideline also concludes that H2 blockers are inferior to proton pump inhibitors for this indication.<xref ref-type="bibr" rid="article-28232.r3">[3]</xref>&#x000a0;(Level II)</p>
        <p>The 2016 Surviving Sepsis Campaign guidelines recommend H2-blockers or proton pump inhibitors be used in patients with risk factors for stress ulcer prophylaxis.<xref ref-type="bibr" rid="article-28232.r4">[4]</xref>&#x000a0;(Level II)</p>
        <p>The 2016 American Society of Anesthesiologists guideline for obstetric anesthesia suggest consideration of non-particulate antacids, H2 blockers and/or metoclopramide to prevent aspiration.<xref ref-type="bibr" rid="article-28232.r6">[6]</xref>&#x000a0;(Level II)</p>
      </sec>
      <sec id="article-28232.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28232&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28232">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28232/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28232">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28232.s10">
        <title>References</title>
        <ref id="article-28232.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Burks</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Feldweg</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Greenberger</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Ledford</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sheffer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Blessing-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tilles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and management of anaphylaxis practice parameter: 2010 update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>126</volume>
            <issue>3</issue>
            <fpage>477</fpage>
            <page-range>477-80.e1-42</page-range>
            <pub-id pub-id-type="pmid">20692689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>Joint Task Force on Practice Parameters</collab>
            <collab>American Academy of Allergy, Asthma and Immunology</collab>
            <collab>American College of Allergy, Asthma and Immunology</collab>
            <collab>Joint Council of Allergy, Asthma and Immunology</collab>
            <article-title>The diagnosis and management of anaphylaxis: an updated practice parameter.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>115</volume>
            <issue>3 Suppl 2</issue>
            <fpage>S483</fpage>
            <page-range>S483-523</page-range>
            <pub-id pub-id-type="pmid">15753926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanza</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Quigley</surname>
                <given-names>EM</given-names>
              </name>
              <collab>Practice Parameters Committee of the American College of Gastroenterology</collab>
            </person-group>
            <article-title>Guidelines for prevention of NSAID-related ulcer complications.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>104</volume>
            <issue>3</issue>
            <fpage>728</fpage>
            <page-range>728-38</page-range>
            <pub-id pub-id-type="pmid">19240698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rhodes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Alhazzani</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sevransky</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sprung</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Nunnally</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rochwerg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rubenfeld</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Angus</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Annane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beale</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bellinghan</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Chiche</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Coopersmith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Fujishima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hidalgo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hollenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Karnad</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kleinpell</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lisboa</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mazuski</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Myburgh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Navalesi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Osborn</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Perner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plunkett</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ranieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schorr</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Seckel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Shieh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shukri</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>SQ</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Van der Poll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wiersinga</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.</article-title>
            <source>Intensive Care Med</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-377</page-range>
            <pub-id pub-id-type="pmid">28101605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bookman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kloth</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Kover</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Smolinski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozols</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.</article-title>
            <source>Semin Oncol</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>6 Suppl 19</issue>
            <fpage>S19</fpage>
            <page-range>S19-13-S19-15</page-range>
            <pub-id pub-id-type="pmid">9427258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <article-title>Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology.</article-title>
            <source>Anesthesiology</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>270</fpage>
            <page-range>270-300</page-range>
            <pub-id pub-id-type="pmid">26580836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crowther</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bellanger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Szauter</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>In vitro stability of ranitidine hydrochloride in enteral nutrient formulas.</article-title>
            <source>Ann Pharmacother</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>859</fpage>
            <page-range>859-62</page-range>
            <pub-id pub-id-type="pmid">8547732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allwood</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>H</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Factors influencing the stability of ranitidine in TPN mixtures.</article-title>
            <source>Clin Nutr</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-6</page-range>
            <pub-id pub-id-type="pmid">16843929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>63</volume>
            <issue>11</issue>
            <fpage>2227</fpage>
            <page-range>2227-46</page-range>
            <pub-id pub-id-type="pmid">26446832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lam</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Corley</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Dec</month>
            <day>11</day>
            <volume>310</volume>
            <issue>22</issue>
            <fpage>2435</fpage>
            <page-range>2435-42</page-range>
            <pub-id pub-id-type="pmid">24327038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Acid-Suppressive Drug Use During Pregnancy and the Risk of Childhood Asthma: A Meta-analysis.</article-title>
            <source>Pediatrics</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29326337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Two cases of h(2)-receptor antagonist hypersensitivity and cross-reactivity.</article-title>
            <source>Allergy Asthma Immunol Res</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-31</page-range>
            <pub-id pub-id-type="pmid">21461253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demirkan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karakaya</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kalyoncu</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2006</year>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-9</page-range>
            <pub-id pub-id-type="pmid">16784015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28232.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>631</fpage>
            <page-range>631-9</page-range>
            <pub-id pub-id-type="pmid">26764898</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
